# Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

> **NCT05728736** · PHASE2 · WITHDRAWN · sponsor: **Brendan Lucey**

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Lemborexant 25 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05728736
- **Lead sponsor:** Brendan Lucey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03-01
- **Primary completion:** 2023-09-27
- **Final completion:** 2023-10-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was terminated due to enrollment difficulties and the inability to obtain necessary study supplies. Five participants signed consent; however, no one was randomized. The study was officially terminated with the funding source on 10/04/2023.
- **Last updated:** 2023-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05728736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05728736, "Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05728736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*